Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dostarlimab (Primary) ; LB 100 (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions

25 Feb 2025 According to a LIXTE Biotechnology media release, company has announced that it has added the Robert H. Lurie Comprehensive Cancer Center (Lurie Cancer Center) of Northwestern University as a second site in a clinical trial combining the Company proprietary compound LB-100 with Dostarlimab (GSK) to treat ovarian clear cell cancer, Emily M. Hinchcliff, MD, MPH, will lead the clinical trial at Lurie Cancer Center.
27 Feb 2024 Planned End Date changed from 31 Jan 2025 to 31 Jan 2026.
27 Feb 2024 Planned primary completion date changed from 31 Jan 2025 to 31 Jan 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com